Aaron Gal
Stock Analyst at Bernstein
(2.20)
# 2,719
Out of 4,761 analysts
22
Total ratings
53.85%
Success rate
6.83%
Average return
Main Sectors:
Stocks Rated by Aaron Gal
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| GILD Gilead Sciences | Initiates: Outperform | $105 | $109.95 | -4.50% | 6 | Oct 17, 2024 | |
| ABBV AbbVie | Initiates: Market Perform | $203 | $202.08 | +0.46% | 2 | Oct 17, 2024 | |
| AMGN Amgen | Initiates: Outperform | $380 | $303.01 | +25.41% | 3 | Oct 17, 2024 | |
| REGN Regeneron Pharmaceuticals | Initiates: Outperform | $1,125 | $700.33 | +60.64% | 3 | Mar 11, 2024 | |
| BIIB Biogen | Upgrades: Outperform | $500 | $140.64 | +255.52% | 6 | Jun 11, 2021 | |
| VTRS Viatris | Initiates: Market Perform | $21 | $11.25 | +86.67% | 1 | Dec 14, 2020 | |
| TEVA Teva Pharmaceutical Industries | Downgrades: Market Perform | n/a | $16.74 | - | 1 | Aug 4, 2017 |
Gilead Sciences
Oct 17, 2024
Initiates: Outperform
Price Target: $105
Current: $109.95
Upside: -4.50%
AbbVie
Oct 17, 2024
Initiates: Market Perform
Price Target: $203
Current: $202.08
Upside: +0.46%
Amgen
Oct 17, 2024
Initiates: Outperform
Price Target: $380
Current: $303.01
Upside: +25.41%
Regeneron Pharmaceuticals
Mar 11, 2024
Initiates: Outperform
Price Target: $1,125
Current: $700.33
Upside: +60.64%
Biogen
Jun 11, 2021
Upgrades: Outperform
Price Target: $500
Current: $140.64
Upside: +255.52%
Viatris
Dec 14, 2020
Initiates: Market Perform
Price Target: $21
Current: $11.25
Upside: +86.67%
Teva Pharmaceutical Industries
Aug 4, 2017
Downgrades: Market Perform
Price Target: n/a
Current: $16.74
Upside: -